Tessa Goetghebuer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Tessa Goetghebuer has a total of 200 co-authors. Here are the top co-authors by number of shared publications:
Jack Levy
Department of Pediatrics, Centre Hospitalier Universitaire Saint-Pierre, Université Libre de Bruxelles (ULB), Brussels, Belgium
5 shared publicationsCatherine Adler
Department of Pediatrics Centre Hospitalier Universitaire Saint‐Pierre Université Libre de Bruxelles Brussels Belgium
3 shared publicationsLuminita Ene
Affiliation Victor Babes Hospital, Bucharest, Romania
3 shared publicationsMarc Hainaut
St Pierre Hospital, Université Libre de Bruxelles, Brussels, Belgium
3 shared publicationsPatricia Barlow
Department of Obstetrics, Centre Hospitalier Universitaire Saint-Pierre, Université Libre de Bruxelles (ULB), Brussels, Belgium
3 shared publications- Ali Judd
MRC Clinical Trials Unit at UCL University College London London UK
2 shared publications
Latest Publications
- 29 April 2026
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 234 (1) , 101-111
Decreased Persistence of Maternal Antibodies in Infants Who Are HIV Exposed and Uninfected
Background: Infants who are HIV exposed but uninfected (iHEU) are more susceptible to severe infections in the first months of life when compared with infants who are HIV unexposed. Previous studies showed an association with reduced transplacental transfer of maternal antibodies. Whether maternal HIV infection also affects the persistence of transferred maternal antibodies is unknown. Methods: Serum samples were collected from 58 mother-infant pairs at delivery (maternal and cord blood) and at 1 month of age. A multiplex assay was established to test the levels of immunoglobulin G against tetanus, pertussis, cytomegalovirus, respiratory syncytial virus, and HIV. Results: When compared with infants who were HIV unexposed, iHEU had significantly lower antigen-specific antibody concentrations at 1 month across targeted pathogens, independent of maternal baselines and gestational ages. Impaired placental transfer and persistence of maternal antibodies contributed to the lower antibody levels in iHEU. Timing of antiretroviral therapy (ART) initiation in mothers had a profound impact on the dynamics of antibodies in iHEU. When compared with initiation of ART before pregnancy, iHEU whose mothers initiated ART during pregnancy had the lowest antibody concentrations at 1 month. Conclusions: Our study shows that in addition to reduced placental transfer, maternal HIV infection is associated with reduced persistence of maternal antibodies after birth. This reduction could contribute to the increased susceptibility of iHEU to severe infections and supports the need to offer vaccination during pregnancy to women with HIV. Our data provide encouragement for screening of HIV infection and initiation of ART before pregnancy to enhance immunity transferred to iHEU.
- 29 April 2026
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 234 (1) , 101-111
Decreased Persistence of Maternal Antibodies in Infants Who Are HIV Exposed and Uninfected
Background: Infants who are HIV exposed but uninfected (iHEU) are more susceptible to severe infections in the first months of life when compared with infants who are HIV unexposed. Previous studies showed an association with reduced transplacental transfer of maternal antibodies. Whether maternal HIV infection also affects the persistence of transferred maternal antibodies is unknown. Methods: Serum samples were collected from 58 mother-infant pairs at delivery (maternal and cord blood) and at 1 month of age. A multiplex assay was established to test the levels of immunoglobulin G against tetanus, pertussis, cytomegalovirus, respiratory syncytial virus, and HIV. Results: When compared with infants who were HIV unexposed, iHEU had significantly lower antigen-specific antibody concentrations at 1 month across targeted pathogens, independent of maternal baselines and gestational ages. Impaired placental transfer and persistence of maternal antibodies contributed to the lower antibody levels in iHEU. Timing of antiretroviral therapy (ART) initiation in mothers had a profound impact on the dynamics of antibodies in iHEU. When compared with initiation of ART before pregnancy, iHEU whose mothers initiated ART during pregnancy had the lowest antibody concentrations at 1 month. Conclusions: Our study shows that in addition to reduced placental transfer, maternal HIV infection is associated with reduced persistence of maternal antibodies after birth. This reduction could contribute to the increased susceptibility of iHEU to severe infections and supports the need to offer vaccination during pregnancy to women with HIV. Our data provide encouragement for screening of HIV infection and initiation of ART before pregnancy to enhance immunity transferred to iHEU.
- 28 March 2025
- Published by Wiley in Pediatric Pulmonology
- Vol. 60 (4) , e71068
Wheezing Episodes in Children Before and After the Onset of the COVID‐19 Pandemic in Brussels
Purpose: Studies have demonstrated important changes in the seasonality of pediatric respiratory illnesses since the onset of the COVID‐19 pandemic. The aim of this study was to describe the epidemiology of childhood wheezing episodes before and after the start of the COVID‐19 pandemic in relation to their potentially associated environmental triggers.Methods: Files of all children treated with salbutamol for an acute wheezing episode in September and October 2019, 2020, and 2021 were retrospectively reviewed. Infection epidemiology, daily concentrations of air pollutants (NO2, O3, PM10, and PM2.5), and fungal spores were collected over the same time period.Results: In 2021, 298 episodes of wheezing were observed compared to 111 in 2020 and 86 in 2019 (p < 0.001). Compared to 2019, children with wheezing in 2021 were significantly older (p < 0.001), less likely to have a history of recurrent wheezing (p < 0.001) and required less hospitalization (p = 0.034). Adenovirus and SARS‐CoV‐2 were more prevalent in 2021 as compared to 2019 (p < 0.001). The concentration of PM10, PM2.5, and O3 was higher in 2021, as compared to both 2019 and 2020 (p < 0.001) while the concentration of NO2 and airborne spores was lower in 2021 compared to 2019 (p < 0.0001).Conclusion: A threefold increase in wheezing episodes was observed in the autumn post‐COVID (2021) compared to pre‐COVID (2019) together with very high circulation of SARS‐CoV‐2 and a significant increase of PM10, PM2.5, and O3.
- 28 March 2025
- Published by Wiley in Pediatric Pulmonology
- Vol. 60 (4) , e71068
Wheezing Episodes in Children Before and After the Onset of the COVID‐19 Pandemic in Brussels
Purpose: Studies have demonstrated important changes in the seasonality of pediatric respiratory illnesses since the onset of the COVID‐19 pandemic. The aim of this study was to describe the epidemiology of childhood wheezing episodes before and after the start of the COVID‐19 pandemic in relation to their potentially associated environmental triggers.Methods: Files of all children treated with salbutamol for an acute wheezing episode in September and October 2019, 2020, and 2021 were retrospectively reviewed. Infection epidemiology, daily concentrations of air pollutants (NO2, O3, PM10, and PM2.5), and fungal spores were collected over the same time period.Results: In 2021, 298 episodes of wheezing were observed compared to 111 in 2020 and 86 in 2019 (p < 0.001). Compared to 2019, children with wheezing in 2021 were significantly older (p < 0.001), less likely to have a history of recurrent wheezing (p < 0.001) and required less hospitalization (p = 0.034). Adenovirus and SARS‐CoV‐2 were more prevalent in 2021 as compared to 2019 (p < 0.001). The concentration of PM10, PM2.5, and O3 was higher in 2021, as compared to both 2019 and 2020 (p < 0.001) while the concentration of NO2 and airborne spores was lower in 2021 compared to 2019 (p < 0.0001).Conclusion: A threefold increase in wheezing episodes was observed in the autumn post‐COVID (2021) compared to pre‐COVID (2019) together with very high circulation of SARS‐CoV‐2 and a significant increase of PM10, PM2.5, and O3.
- 16 May 2024
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 43 (9) , e307-e309
SARS-CoV-2 Infection in Children Less Than Forty Days Hospitalized in Belgium Between 2020 and 2022
Our study aimed to assess the severity of severe acute respiratory syndrome coronavirus 2 infection in hospitalized infants under 40 days old, across 21 Belgian hospitals between 2020 and 2022. Of the 365 infants studied, 14.2% needed respiratory support. The median hospital stay was 3 days (interquartile range, 2–4), and there were no deaths. Infection severity was similar during the Omicron and Alpha/Delta periods.
- 16 May 2024
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 43 (9) , e307-e309
SARS-CoV-2 Infection in Children Less Than Forty Days Hospitalized in Belgium Between 2020 and 2022
Our study aimed to assess the severity of severe acute respiratory syndrome coronavirus 2 infection in hospitalized infants under 40 days old, across 21 Belgian hospitals between 2020 and 2022. Of the 365 infants studied, 14.2% needed respiratory support. The median hospital stay was 3 days (interquartile range, 2–4), and there were no deaths. Infection severity was similar during the Omicron and Alpha/Delta periods.
- Open Access
Gen Z and HIV—Strategies for Optimizing the Care of the Next Generation of Adolescents Living with HIV
The management of adolescents living with HIV represents a particular challenge in the global response to HIV. The challenges specific to this age group include difficulties engaging and maintaining them in care, challenges with transition to adult care, and limited therapeutic options for treatment-experienced patients, all of which have been jeopardized by the COVID-19 pandemic. This paper summarizes some of the challenges in managing adolescents living with HIV, as well as some of the most recent and innovative therapeutic approaches in this population.
Open AccessGen Z and HIV—Strategies for Optimizing the Care of the Next Generation of Adolescents Living with HIV
The management of adolescents living with HIV represents a particular challenge in the global response to HIV. The challenges specific to this age group include difficulties engaging and maintaining them in care, challenges with transition to adult care, and limited therapeutic options for treatment-experienced patients, all of which have been jeopardized by the COVID-19 pandemic. This paper summarizes some of the challenges in managing adolescents living with HIV, as well as some of the most recent and innovative therapeutic approaches in this population.
- Open Access
- 24 August 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-11
SARS-CoV-2 vaccination elicits broad and potent antibody effector functions to variants of concern in vulnerable populations
SARS-CoV-2 variants have continuously emerged in the face of effective vaccines. Reduced neutralization against variants raises questions as to whether other antibody functions are similarly compromised, or if they might compensate for lost neutralization activity. Here, the breadth and potency of antibody recognition and effector function is surveyed following either infection or vaccination. Considering pregnant women as a model cohort with higher risk of severe illness and death, we observe similar binding and functional breadth for healthy and immunologically vulnerable populations, but considerably greater functional antibody breadth and potency across variants associated with vaccination. In contrast, greater antibody functional activity targeting the endemic coronavirus OC43 is noted among convalescent individuals, illustrating a dichotomy in recognition between close and distant human coronavirus strains associated with exposure history. This analysis of antibody functions suggests the differential potential for antibody effector functions to contribute to protecting vaccinated and convalescent subjects as novel variants continue to evolve.
- 24 August 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-11
Open AccessSARS-CoV-2 vaccination elicits broad and potent antibody effector functions to variants of concern in vulnerable populations
SARS-CoV-2 variants have continuously emerged in the face of effective vaccines. Reduced neutralization against variants raises questions as to whether other antibody functions are similarly compromised, or if they might compensate for lost neutralization activity. Here, the breadth and potency of antibody recognition and effector function is surveyed following either infection or vaccination. Considering pregnant women as a model cohort with higher risk of severe illness and death, we observe similar binding and functional breadth for healthy and immunologically vulnerable populations, but considerably greater functional antibody breadth and potency across variants associated with vaccination. In contrast, greater antibody functional activity targeting the endemic coronavirus OC43 is noted among convalescent individuals, illustrating a dichotomy in recognition between close and distant human coronavirus strains associated with exposure history. This analysis of antibody functions suggests the differential potential for antibody effector functions to contribute to protecting vaccinated and convalescent subjects as novel variants continue to evolve.
- Open Access
- 14 May 2021
- Published by Wiley in Developmental Medicine & Child Neurology
- Vol. 63 (10) , 1161-1170
Neurological development of children who are HIV‐exposed and uninfected
Widespread use of antiretroviral drugs for pregnant/breastfeeding females with human immunodeficiency virus (HIV) has led to declining vertical transmission. Despite being HIV‐uninfected, the increasing number of children who are HIV‐exposed and uninfected (CHEU) often present with developmental alterations. We review seminal and recent evidence on the neurological development of CHEU and associations with early life HIV/antiretroviral exposure. Our conceptual model highlights the numerous exposures and universal risk factors for CHEU developmental disorders. Early studies suggest a significant association between HIV exposure and neurological abnormalities, varying according to the burden of HIV‐specific exposures and other risk factors. More recent observations from the modern era are inconsistent, although some studies suggest specific antiretrovirals may adversely affect neurological development of CHEU. As the CHEU population continues to grow, alongside simultaneous increases in types and combinations of antiretrovirals used in pregnancy, long‐term monitoring of CHEU is necessary for understanding the effects of HIV/antiretroviral exposure on CHEU developmental outcomes. What this paper adds: Evidence on the neurological development of children who are human immunodeficiency virus (HIV)‐exposed and uninfected (CHEU) is synthesized. Comparisons are made to children who are HIV‐unexposed, across treatment eras and settings, and by antiretroviral drug regimens and drug classes. CHEU exposures are complex and include HIV‐specific and universal risk factors which may affect development during the early years of life.
- 14 May 2021
- Published by Wiley in Developmental Medicine & Child Neurology
- Vol. 63 (10) , 1161-1170
Open AccessNeurological development of children who are HIV‐exposed and uninfected
Widespread use of antiretroviral drugs for pregnant/breastfeeding females with human immunodeficiency virus (HIV) has led to declining vertical transmission. Despite being HIV‐uninfected, the increasing number of children who are HIV‐exposed and uninfected (CHEU) often present with developmental alterations. We review seminal and recent evidence on the neurological development of CHEU and associations with early life HIV/antiretroviral exposure. Our conceptual model highlights the numerous exposures and universal risk factors for CHEU developmental disorders. Early studies suggest a significant association between HIV exposure and neurological abnormalities, varying according to the burden of HIV‐specific exposures and other risk factors. More recent observations from the modern era are inconsistent, although some studies suggest specific antiretrovirals may adversely affect neurological development of CHEU. As the CHEU population continues to grow, alongside simultaneous increases in types and combinations of antiretrovirals used in pregnancy, long‐term monitoring of CHEU is necessary for understanding the effects of HIV/antiretroviral exposure on CHEU developmental outcomes. What this paper adds: Evidence on the neurological development of children who are human immunodeficiency virus (HIV)‐exposed and uninfected (CHEU) is synthesized. Comparisons are made to children who are HIV‐unexposed, across treatment eras and settings, and by antiretroviral drug regimens and drug classes. CHEU exposures are complex and include HIV‐specific and universal risk factors which may affect development during the early years of life.
- 15 November 2020
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 205 (10) , 2618-2628
Innate Immune Responses and Gut Microbiomes Distinguish HIV-Exposed from HIV-Unexposed Children in a Population-Specific Manner
In both high- and low-income countries, HIV-negative children born to HIV-positive mothers (HIV exposed, uninfected [HEU]) are more susceptible to severe infection than HIV-unexposed, uninfected (HUU) children, with altered innate immunity hypothesized to be a cause. Both the gut microbiome and systemic innate immunity differ across biogeographically distinct settings, and the two are known to influence each other. And although the gut microbiome is influenced by HIV infection and may contribute to altered immunity, the biogeography of immune-microbiome correlations among HEU children have not been investigated. To address this, we compared the innate response and the stool microbiome of 2-y-old HEU and HUU children from Belgium, Canada, and South Africa to test the hypothesis that region-specific immune alterations directly correlate to differences in their stool microbiomes. We did not detect a universal immune or microbiome signature underlying differences between HEU versus HUU that was applicable to all children. But as hypothesized, population-specific differences in stool microbiomes were readily detected and included reduced abundances of short-chain fatty acid–producing bacteria in Canadian HEU children. Furthermore, we did not identify innate immune-microbiome associations that distinguished HEU from HUU children in any population. These findings suggest that maternal HIV infection is independently associated with differences in both innate immunity and the stool microbiome in a biogeographical population-specific way.
- 15 November 2020
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 205 (10) , 2618-2628
Innate Immune Responses and Gut Microbiomes Distinguish HIV-Exposed from HIV-Unexposed Children in a Population-Specific Manner
In both high- and low-income countries, HIV-negative children born to HIV-positive mothers (HIV exposed, uninfected [HEU]) are more susceptible to severe infection than HIV-unexposed, uninfected (HUU) children, with altered innate immunity hypothesized to be a cause. Both the gut microbiome and systemic innate immunity differ across biogeographically distinct settings, and the two are known to influence each other. And although the gut microbiome is influenced by HIV infection and may contribute to altered immunity, the biogeography of immune-microbiome correlations among HEU children have not been investigated. To address this, we compared the innate response and the stool microbiome of 2-y-old HEU and HUU children from Belgium, Canada, and South Africa to test the hypothesis that region-specific immune alterations directly correlate to differences in their stool microbiomes. We did not detect a universal immune or microbiome signature underlying differences between HEU versus HUU that was applicable to all children. But as hypothesized, population-specific differences in stool microbiomes were readily detected and included reduced abundances of short-chain fatty acid–producing bacteria in Canadian HEU children. Furthermore, we did not identify innate immune-microbiome associations that distinguished HEU from HUU children in any population. These findings suggest that maternal HIV infection is independently associated with differences in both innate immunity and the stool microbiome in a biogeographical population-specific way.
- Open Access
- 30 November 2018
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 5 (12) , ofy320
Prevalence, Risk Factors, and Serotype Distribution of Group B Streptococcus Colonization in HIV-Infected Pregnant Women Living in Belgium: A Prospective Cohort Study
Background: Group B streptococcus (GBS) infection is a leading cause of severe neonatal infection. Maternal GBS carriage during pregnancy is the main risk factor for both early-onset and late-onset GBS disease. High incidence of GBS infection has been reported in HIV-exposed but -uninfected infants (HEU). We aimed to determine the prevalence, characteristics, and risk factors for GBS colonization in HIV-infected and HIV-uninfected pregnant women living in Belgium. Methods: Between January 1, 2011, and December 31, 2013, HIV-infected (n = 125) and -uninfected (n = 120) pregnant women had recto-vaginal swabs at 35–37 weeks of gestation and at delivery for GBS detection. Demographic, obstetrical, and HIV infection–related data were prospectively collected. GBS capsular serotyping was performed on a limited number of samples (33 from HIV-infected and 16 from HIV-uninfected pregnant women). Results: There was no significant difference in the GBS colonization rate between HIV-infected and -uninfected pregnant women (29.6% vs 24.2%, respectively). HIV-infected women were more frequently colonized by serotype III (36.4% vs 12.5%), and the majority of serotype III strains belonged to the hypervirulent clone ST-17. Exclusively trivalent vaccine serotypes (Ia, Ib, and III) were found in 57.6% and 75% of HIV-infected and -uninfected women, respectively, whereas the hexavalent vaccine serotypes (Ia, Ib, II, III, IV, and V) were found in 97% and 100%, respectively. Conclusions: HIV-infected and -uninfected pregnant women living in Belgium have a similar GBS colonization rate. A trend to a higher colonization rate with serotype III was found in HIV-infected women, and those serotype III strains belong predominantly to the hypervirulent clone ST17.
- 30 November 2018
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 5 (12) , ofy320
Open AccessPrevalence, Risk Factors, and Serotype Distribution of Group B Streptococcus Colonization in HIV-Infected Pregnant Women Living in Belgium: A Prospective Cohort Study
Background: Group B streptococcus (GBS) infection is a leading cause of severe neonatal infection. Maternal GBS carriage during pregnancy is the main risk factor for both early-onset and late-onset GBS disease. High incidence of GBS infection has been reported in HIV-exposed but -uninfected infants (HEU). We aimed to determine the prevalence, characteristics, and risk factors for GBS colonization in HIV-infected and HIV-uninfected pregnant women living in Belgium. Methods: Between January 1, 2011, and December 31, 2013, HIV-infected (n = 125) and -uninfected (n = 120) pregnant women had recto-vaginal swabs at 35–37 weeks of gestation and at delivery for GBS detection. Demographic, obstetrical, and HIV infection–related data were prospectively collected. GBS capsular serotyping was performed on a limited number of samples (33 from HIV-infected and 16 from HIV-uninfected pregnant women). Results: There was no significant difference in the GBS colonization rate between HIV-infected and -uninfected pregnant women (29.6% vs 24.2%, respectively). HIV-infected women were more frequently colonized by serotype III (36.4% vs 12.5%), and the majority of serotype III strains belonged to the hypervirulent clone ST-17. Exclusively trivalent vaccine serotypes (Ia, Ib, and III) were found in 57.6% and 75% of HIV-infected and -uninfected women, respectively, whereas the hexavalent vaccine serotypes (Ia, Ib, II, III, IV, and V) were found in 97% and 100%, respectively. Conclusions: HIV-infected and -uninfected pregnant women living in Belgium have a similar GBS colonization rate. A trend to a higher colonization rate with serotype III was found in HIV-infected women, and those serotype III strains belong predominantly to the hypervirulent clone ST17.
- Open Access
- 26 March 2018
- Published by Wiley in Acta Paediatrica
- Vol. 107 (9) , 1490-1491
Assessing the health of internationally adopted children
- 26 March 2018
- Published by Wiley in Acta Paediatrica
- Vol. 107 (9) , 1490-1491
Open AccessAssessing the health of internationally adopted children
- Open Access
- 1 March 2018
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 15 (3) , e1002514
The epidemiology of adolescents living with perinatally acquired HIV: A cross-region global cohort analysis
Globally, the population of adolescents living with perinatally acquired HIV (APHs) continues to expand. In this study, we pooled data from observational pediatric HIV cohorts and cohort networks, allowing comparisons of adolescents with perinatally acquired HIV in “real-life” settings across multiple regions. We describe the geographic and temporal characteristics and mortality outcomes of APHs across multiple regions, including South America and the Caribbean, North America, Europe, sub-Saharan Africa, and South and Southeast Asia. Through the Collaborative Initiative for Paediatric HIV Education and Research (CIPHER), individual retrospective longitudinal data from 12 cohort networks were pooled. All children infected with HIV who entered care before age 10 years, were not known to have horizontally acquired HIV, and were followed up beyond age 10 years were included in this analysis conducted from May 2016 to January 2017. Our primary analysis describes patient and treatment characteristics of APHs at key time points, including first HIV-associated clinic visit, antiretroviral therapy (ART) start, age 10 years, and last visit, and compares these characteristics by geographic region, country income group (CIG), and birth period. Our secondary analysis describes mortality, transfer out, and lost to follow-up (LTFU) as outcomes at age 15 years, using competing risk analysis. Among the 38,187 APHs included, 51% were female, 79% were from sub-Saharan Africa and 65% lived in low-income countries. APHs from 51 countries were included (Europe: 14 countries and 3,054 APHs; North America: 1 country and 1,032 APHs; South America and the Caribbean: 4 countries and 903 APHs; South and Southeast Asia: 7 countries and 2,902 APHs; sub-Saharan Africa, 25 countries and 30,296 APHs). Observation started as early as 1982 in Europe and 1996 in sub-Saharan Africa, and continued until at least 2014 in all regions. The median (interquartile range [IQR]) duration of adolescent follow-up was 3.1 (1.5–5.2) years for the total cohort and 6.4 (3.6–8.0) years in Europe, 3.7 (2.0–5.4) years in North America, 2.5 (1.2–4.4) years in South and Southeast Asia, 5.0 (2.7–7.5) years in South America and the Caribbean, and 2.1 (0.9–3.8) years in sub-Saharan Africa. Median (IQR) age at first visit differed substantially by region, ranging from 0.7 (0.3–2.1) years in North America to 7.1 (5.3–8.6) years in sub-Saharan Africa. The median age at ART start varied from 0.9 (0.4–2.6) years in North America to 7.9 (6.0–9.3) years in sub-Saharan Africa. The cumulative incidence estimates (95% confidence interval [CI]) at age 15 years for mortality, transfers out, and LTFU for all APHs were 2.6% (2.4%–2.8%), 15.6% (15.1%–16.0%), and 11.3% (10.9%–11.8%), respectively. Mortality was lowest in Europe (0.8% [0.5%–1.1%]) and highest in South America and the Caribbean (4.4% [3.1%–6.1%]). However, LTFU was lowest in South America and the Caribbean (4.8% [3.4%–6.7%]) and highest in sub-Saharan Africa (13.2% [12.6%–13.7%]). Study limitations include the high LTFU rate in sub-Saharan Africa, which could have affected the comparison of mortality across regions; inclusion of data only for APHs receiving ART from some countries; and unavailability of data from high-burden countries such as Nigeria. To our knowledge, our study represents the largest multiregional epidemiological analysis of APHs. Despite probable under-ascertained mortality, mortality in APHs remains substantially higher in sub-Saharan Africa, South and Southeast Asia, and South America and the Caribbean than in Europe. Collaborations such as CIPHER enable us to monitor current global temporal trends in outcomes over time to inform appropriate policy responses.
- 1 March 2018
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 15 (3) , e1002514
Open AccessThe epidemiology of adolescents living with perinatally acquired HIV: A cross-region global cohort analysis
Globally, the population of adolescents living with perinatally acquired HIV (APHs) continues to expand. In this study, we pooled data from observational pediatric HIV cohorts and cohort networks, allowing comparisons of adolescents with perinatally acquired HIV in “real-life” settings across multiple regions. We describe the geographic and temporal characteristics and mortality outcomes of APHs across multiple regions, including South America and the Caribbean, North America, Europe, sub-Saharan Africa, and South and Southeast Asia. Through the Collaborative Initiative for Paediatric HIV Education and Research (CIPHER), individual retrospective longitudinal data from 12 cohort networks were pooled. All children infected with HIV who entered care before age 10 years, were not known to have horizontally acquired HIV, and were followed up beyond age 10 years were included in this analysis conducted from May 2016 to January 2017. Our primary analysis describes patient and treatment characteristics of APHs at key time points, including first HIV-associated clinic visit, antiretroviral therapy (ART) start, age 10 years, and last visit, and compares these characteristics by geographic region, country income group (CIG), and birth period. Our secondary analysis describes mortality, transfer out, and lost to follow-up (LTFU) as outcomes at age 15 years, using competing risk analysis. Among the 38,187 APHs included, 51% were female, 79% were from sub-Saharan Africa and 65% lived in low-income countries. APHs from 51 countries were included (Europe: 14 countries and 3,054 APHs; North America: 1 country and 1,032 APHs; South America and the Caribbean: 4 countries and 903 APHs; South and Southeast Asia: 7 countries and 2,902 APHs; sub-Saharan Africa, 25 countries and 30,296 APHs). Observation started as early as 1982 in Europe and 1996 in sub-Saharan Africa, and continued until at least 2014 in all regions. The median (interquartile range [IQR]) duration of adolescent follow-up was 3.1 (1.5–5.2) years for the total cohort and 6.4 (3.6–8.0) years in Europe, 3.7 (2.0–5.4) years in North America, 2.5 (1.2–4.4) years in South and Southeast Asia, 5.0 (2.7–7.5) years in South America and the Caribbean, and 2.1 (0.9–3.8) years in sub-Saharan Africa. Median (IQR) age at first visit differed substantially by region, ranging from 0.7 (0.3–2.1) years in North America to 7.1 (5.3–8.6) years in sub-Saharan Africa. The median age at ART start varied from 0.9 (0.4–2.6) years in North America to 7.9 (6.0–9.3) years in sub-Saharan Africa. The cumulative incidence estimates (95% confidence interval [CI]) at age 15 years for mortality, transfers out, and LTFU for all APHs were 2.6% (2.4%–2.8%), 15.6% (15.1%–16.0%), and 11.3% (10.9%–11.8%), respectively. Mortality was lowest in Europe (0.8% [0.5%–1.1%]) and highest in South America and the Caribbean (4.4% [3.1%–6.1%]). However, LTFU was lowest in South America and the Caribbean (4.8% [3.4%–6.7%]) and highest in sub-Saharan Africa (13.2% [12.6%–13.7%]). Study limitations include the high LTFU rate in sub-Saharan Africa, which could have affected the comparison of mortality across regions; inclusion of data only for APHs receiving ART from some countries; and unavailability of data from high-burden countries such as Nigeria. To our knowledge, our study represents the largest multiregional epidemiological analysis of APHs. Despite probable under-ascertained mortality, mortality in APHs remains substantially higher in sub-Saharan Africa, South and Southeast Asia, and South America and the Caribbean than in Europe. Collaborations such as CIPHER enable us to monitor current global temporal trends in outcomes over time to inform appropriate policy responses.